On Thursday, ADT Corp (NYSE:ADT)’s shares declined -0.54% to $36.52.
ADT Corp (ADT) declared that the U.S. District Court for the Southern District of Florida (the “Court”) granted the motions made by ADT and the other defendants to dismiss the merged complaint in the securities class action captioned Phillip Henningsen v. The ADT Corporation.
The ADT Corporation provides monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. The company’s monitored security and home/business automation offerings comprise the installation and monitoring of residential and business security, and premises automation systems designed to detect intrusion, control access and react to movement, smoke, carbon monoxide, flooding, temperature, and other environmental conditions and hazards, in addition to to address personal emergencies, such as injuries, medical emergencies, or incapacitation.
Nektar Therapeutics (NASDAQ:NKTR)’s shares dropped -2.56% to $11.44.
Nektar Therapeutics (NKTR) and The University of Texas MD Anderson Cancer Center recently declared a research partnershipthat comprises a Phase 1/2 clinical study to evaluate NKTR-214, a CD122-biased cytokine designed to preferentially stimulate production of CD8-positive T cells, which are tumor killing cells found naturally in the body. CD122, which is also known as the Interleukin-2 receptor beta sub-unit, is a key signaling receptor that is known to enhance proliferation of these effector T cells.1
The agreement covers a Phase 1/2 study to evaluate NKTR-214 in a variety of tumor types as a monotherapy and in combination with other therapies, counting PD-1 pathway inhibitors. Nektar and MD Anderson expect to initiate the first dose-escalation clinical study later this year. The two organizations will also conduct translational research to identify predictive biomarkers that can be used in the future development of NKTR-214.
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
At the end of Thursday’s trade, Incyte Corporation (NASDAQ:INCY)‘s shares dipped -1.96% to $106.84.
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, declared the clearance of the Investigational New Drug (IND) application by the United States Food and Drug Administration (FDA) to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation’s (INCY) investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer.
In February 2015, Advaxis and Incyte reached a non-exclusive clinical trial partnershipagreement to evaluate the combination of ADXS-HPV with epacadostat for the treatment of cervical cancer. The projected Phase 2 protocol is designed as a multicenter, open-label, preoperative window-study designed to evaluate the safety and efficacy of ADXS-HPV as monotherapy and in combination with epacadostat in about 30 patients with Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer. The results will be used to determine whether further clinical development of this combination is warranted.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), counting primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF.
Vertex Pharmaceuticals Incorporated(NASDAQ:VRTX), ended its Thursday’s trading session with 0.02% loss, and closed at $126.94.
Vertex Pharmaceuticals Incorporated (VRTX) and Parion Sciences recently declared that the companies will collaborate to develop investigational epithelial sodium channel (ENaC) inhibitors for the potential treatment of cystic fibrosis (CF) and other pulmonary diseases. Under the agreement, Vertex gains worldwide development and commercial rights to Parion’s investigational ENaC inhibitors, counting P-1037 and P-1055, for CF and other pulmonary diseases. P-1037 is presently being evaluated in an exploratory Phase 2a study in people with CF, regardless of genotype. Vertex and Parion plan to start an additional Phase 2a study that adds P-1037 to treatment with the investigational combination of lumacaftor and ivacaftor for people with CF who have two copies of the F508del mutation. Parion will receive an $80 million up-front payment from Vertex with the potential to receive additional development and regulatory milestone payments and tiered royalties related to P-1037 and P-1055 in CF and other pulmonary diseases.
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
